Profile Response Detail

Molecular Profile KRAS mutant
Therapy MEHD7945A + Cobimetinib
Indication/Tumor Type Advanced Solid Tumor
Response Type no benefit
Create By tyin
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant Advanced Solid Tumor no benefit MEHD7945A + Cobimetinib Phase I Actionable In a Phase I trial, Duligotuzumab (MEHD7945A) and Cotellic (cobimetinib) combination therapy demonstrated limited safety and efficacy, with stable disease as best response in 41% (9/22) of patients with KRAS-mutant solid tumors (PMID: 28592615; NCT01986166). 28592615
PubMed Id Reference Title Details
(28592615) A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Full reference...